195615-84-0

The pre-administration of Blarcamesine leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg^[1]. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1?mg/kg. One day after injections, the significant Aβ_25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1?mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser⁹ phosphorylation induced by the peptide at 0.3 and 1?mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ_25-35-induced increase in Aβ_1-42 content, with a significant effect at the highest dose tested^[2].